论文部分内容阅读
目的:研究左乙拉西坦对热性惊厥患儿的临床疗效及对血清神经元特异性烯醇化酶(NSE)的影响。方法:2011年1月—2014年12月在本儿科就诊的热性惊厥患儿128例随机分为观察组和对照组,对照组患儿均进行常规治疗,观察组患儿在对症治疗的基础上加用左乙拉西坦片,比较两组患儿惊厥复发的情况,治疗前后两组患者脑电图异常比例以及血清NSE水平。结果:治疗前两组患儿脑电图异常比例以及血清NSE水平比较的差异无统计学意义(P>0.05),治疗后观察组患儿惊厥复发的比例、惊厥平均持续时间、脑电图异常比例以及血清NSE水平均较对照组显著降低(均P<0.01)。结论:左乙拉西坦对热性惊厥患儿具有较好的临床疗效,并且可以显著降低患儿脑电图异常的发生,并且降低患儿血清神经元特异性烯醇化酶水平。
Objective: To investigate the clinical efficacy of levetiracetam in children with febrile seizures and its effect on serum neuron-specific enolase (NSE). Methods: From January 2011 to December 2014, 128 children with febrile seizures in our pediatric department were randomly divided into observation group and control group. Children in control group were treated routinely. The treatment group Addition of levetiracetam on the two groups of children with recurrent seizures, EEG abnormalities before and after treatment in both groups and serum NSE levels. Results: There was no significant difference in EEG abnormalities and serum NSE levels between the two groups before treatment (P> 0.05). After treatment, the proportion of recurrent seizures, the mean seizure duration, the abnormal EEG Ratio and serum NSE levels were significantly lower than the control group (all P <0.01). CONCLUSION: Levetiracetam has a good clinical efficacy in children with febrile seizures, and can significantly reduce the occurrence of EEG abnormalities in children and reduce the level of serum neuron-specific enolase in children.